Intuitive Surgical Earnings: Can da Vinci Bounce Back?

Intuitive Surgical suffered a big setback last year, but will long-term investors' faith in the da Vinci surgical system prove justified?

Jan 21, 2014 at 6:30PM

Intuitive Surgical (NASDAQ:ISRG) will release its quarterly report on Thursday, and investors hope that the robotic-surgical company is able to mount a turnaround after a tough 2013. Even as controversy continues to swirl over the future of robotics in surgery, the completion of Stryker's (NYSE:SYK) takeover of MAKO Surgical and the continued growth in Accuray (NASDAQ:ARAY) indicate the optimism that many industry players have in the technology. Still, with competition from Johnson & Johnson (NYSE:JNJ) and Covidien potentially making robotic surgery less attractive in its key focus areas, Intuitive Surgical earnings could still remain under pressure until the company can reassure medical professionals that the technology is sound, safe, and advantageous for patients.

For years, Intuitive Surgical was a growth leader in the medical-device industry, with seemingly unlimited growth potential as its da Vinci surgical system gained acceptance and became more extensively used in the medical profession. But the high cost of the system made hospitals hesitant to make large capital expenditures to obtain systems during the recent recession, and the ongoing transformation in the health-care industry has cast a shadow over Intuitive Surgical. At the same time, an FDA investigation also contributed to falling sales. Let's take an early look at what's been happening with Intuitive Surgical over the past quarter and what we're likely to see in its report.

Stats on Intuitive Surgical

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$558.66 million

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

What's next for Intuitive Surgical earnings?
In recent months, analysts have been less than certain about the prospects for Intuitive Surgical earnings, cutting almost a quarter per share from their full-year 2014 estimates. The stock, though, has rebounded, rising 10% since mid-October.

Nearly all of the gains in the stock came when Intuitive Surgical gave its preliminary figures for the just-completed fourth quarter. Even though the company said that revenue would fall about 5% from year-ago levels, Intuitive Surgical said that gains in sales from instruments and accessories rose 6%, reflecting the 16% rise in surgical-procedure volume the company experienced for the full 2013 year. Service revenue also gained, helping to offset another big drop of more than 20% in da Vinci system sales for the quarter. That trend was similar to what Intuitive Surgical saw in the third quarter, with a 32% drop in systems revenue weighing against double-digit percentage gains in services and instruments and accessories sales.


Source: Intuitive Surgical.

Despite its struggles, though, Intuitive Surgical's fundamentals still look stronger than its peers. Before Stryker bought MAKO, the rival surgical device maker was still consistently unprofitable, and revenue growth was somewhat haphazard. Similarly, Accuray has seen its revenue steadily decline over the past couple of years, with continued losses plaguing the small company. By contrast, even with Intuitive Surgical's difficulties, the company is solidly profitable.

Lately, Intuitive Surgical has started to get some support from the medical community. A report in the Journal of Endourology found that certain robotic prostatectomy procedures led to shorter hospital stays and fewer complications than traditional open surgery. Yet some analysts remain unconvinced, pointing instead to uncertainty about reimbursements under federal health-care programs and the possible need for Intuitive Surgical to offer da Vinci systems at discounted prices. Moreover, with Johnson & Johnson and Covidien offering minimally invasive surgical products that can reduce the downsides of open surgery, hospitals could continue to remain skeptical of the need to buy da Vinci systems.

In the Intuitive Surgical earnings report, watch for the company to give more details on exactly what sorts of procedures have been most popular for the da Vinci system. As investors get more comfortable with the trends affecting the industry, they might see more of a long-term upside for Intuitive Surgical -- even if they have to wait until adverse impacts from the Affordable Care Act and other headwinds resolve themselves.

Will Obamacare crush Intuitive Surgical?
The Affordable Care Act has complex provisions that have affected Intuitive Surgical and other medical-device makers. In only minutes, you can learn the critical facts you need to know in a special free report called "Everything You Need to Know About Obamacare." This FREE guide contains the key information and money-making advice that every American must know. Please click here to access your free copy.

Click here to add Intuitive Surgical to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends and owns shares of Intuitive Surgical and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information